NCT05566314 is a NA clinical trial of Amunizer in Immune, sponsored by Nutraceuticals Research Institute.

Who is sponsoring NCT05566314?

NCT05566314 is sponsored by Nutraceuticals Research Institute.

What drugs are being tested in NCT05566314?

Interventions in NCT05566314: Amunizer, Placebo.

Is NCT05566314 still recruiting?

NCT05566314 is currently status unknown. Last updated 4 October 2022.

Last reviewed 2022-10-04 · How we verify

NCT05566314

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Beverage for Immune Support

Status unknown NA Last updated 4 October 2022

What this trial tests

NA trial testing Amunizer in Immune in 160 participants. Status unknown.

Timeline

22 September 2022

Primary endpoint
31 January 2023

31 March 2023

Quick facts

Lead sponsor	Nutraceuticals Research Institute
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	160
Start date	22 September 2022
Primary completion	31 January 2023
Estimated completion	31 March 2023
Sites	1 location across United States

Drugs / interventions tested

Amunizer
Placebo

Conditions studied

Immune — all drugs for Immune →

Sponsor

Nutraceuticals Research Institute

Who can join

Adults 20 to 65, any sex, with Immune. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate the effects of a beverage supplement on immune health over an 8 week intervention using either a placebo or active supplement.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Immune

Currently open trials in the same condition.

NCT06643247 — Electroacupuncture Regulation of Immune Cells in Herpes Zoster · NA · recruiting

Other Nutraceuticals Research Institute trials

Trials by the same sponsor.

NCT07210229 — The Effectiveness of a Proprietary Ashwagandha Extract on Menopausal Symptoms: A Three-Arm Randomized, Double-Blinded, P · NA · not yet recruiting
NCT06919328 — Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+ · NA · recruiting
NCT06793891 — Effects of Ashwagandha Extract on Stress Levels · NA · recruiting
NCT06894108 — The Effectiveness of a Proprietary of a Botanical Extract on Sleep Quality · NA · completed
NCT06382688 — IV Administration of ChromaDex's Niagen® as Compared to NAD+ · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05566314 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nutraceuticals Research Institute
Last refreshed: 4 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05566314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing